全基因组测序在评估肺纤维化风险与临床结局中的效用
该观察性队列研究对949例特发性或家族性肺纤维化患者行全基因组测序,评估罕见与常见变异及端粒长度。结果显示WGS估计端粒长度与qPCR和Southern blot相关,罕见致病变异见于14%患者且家族史者更高,并与移植无生存期缩短相关。WGS可同时评估遗传风险、端粒相关变异功能效应并预测临床结局。
要点
- WGS可同时检测罕见/常见变异并估计端粒长度,用于肺纤维化风险评估。
- 罕见致病变异见于14%患者,家族史者25%对无家族史者5%。
- 罕见致病变异、qPCR端粒长度短及MUC5B rs35705950缺失与移植无生存期缩短相关。
核心结论
- WGS作为单一检测可提示肺纤维化遗传介导风险,通过估计端粒长度评估端粒相关变异的功能效应,并预测临床相关疾病结局。
研究设计与样本
- 观察性队列研究,对949例特发性肺纤维化或家族性肺纤维化患者行全基因组测序,确定罕见和常见变异基因型、估计端粒长度并分析基因组因素与临床结局的关联。
主要发现
- WGS估计的端粒长度与定量PCR相关(R=0.65),与Southern blot相关(R=0.71)。
- 罕见致病变异见于总队列14%,有家族史者25%对无家族史者5%,增加五倍。
- 大多数罕见致病变异(85%)位于端粒相关基因,并与较短的端粒长度相关。
- 罕见致病变异对端粒长度的影响大于基于20个常见变异计算的多基因风险评分。
- 常见变异多基因风险评分仅在散发性疾病中预测端粒长度。
临床怎么用
- 对特发性或家族性肺纤维化患者,可考虑WGS一次性评估遗传风险、端粒长度及预后相关变异。
- 解读WGS结果时需关注罕见致病变异(尤其端粒相关基因)、qPCR测量端粒长度及MUC5B rs35705950状态以辅助预后判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whole genome sequencing (WGS) can detect variants and estimate telomere length. The clinical utility of WGS in estimating risk, progression and survival of pulmonary fibrosis patients is unknown. METHODS: In this observational cohort study, we performed WGS on 949 patients with idiopathic pulmonary fibrosis or familial pulmonary fibrosis to determine rare and common variant genotypes, estimate telomere length and assess the association of genomic factors with clinical outcomes. RESULTS: WGS estimates of telomere length correlated with quantitative PCR (R=0.65) and Southern blot (R=0.71) measurements. Rare deleterious qualifying variants were found in 14% of the total cohort, with a five-fold increase in those with a family history of disease versus those without (25% versus 5%). Most rare qualifying variants (85%) were found in telomere-related genes and were associated with shorter telomere lengths. Rare qualifying variants had a greater effect on telomere length than a polygenic risk score calculated using 20 common variants previously associated with telomere length. The common variant polygenic risk score predicted telomere length only in sporadic disease. Reduced transplant-free survival was associated with rare qualifying variants, shorter quantitative PCR-measured telomere lengths and absence of the MUC5B promoter (rs35705950) single nucleotide polymorphism, but not with WGS-estimated telomere length or the common variant polygenic risk score. Disease progression was associated with both measures of telomere length (quantitative PCR measured and WGS estimated), rare qualifying variants and the common variant polygenic risk score. CONCLUSION: As a single test, WGS can inform pulmonary fibrosis genetic-mediated risk, evaluate the functional effect of telomere-related variants by estimating telomere length, and prognosticate clinically relevant disease outcomes.
引用
- Zhang D, Newton CA, Wang B, et al. Utility of whole genome sequencing in assessing risk and clinically relevant outcomes for pulmonary fibrosis. Eur Respir J. 2022. PMID: 36028256. doi:10.1183/13993003.00577-2022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。